Insider transactions

EDGAR

Scribe Therapeutics, Inc.

Transactions reported by directors, officers and 10% owners on SEC Forms 3, 4 and 5, read from each filing’s XML. Codes and their wording are the SEC’s own.

A Form 4 is due within two business days of the transaction, so the most recent trades may not be filed yet.

Window: transactions dated on or after 2025-11-18.

Open-market purchases (code P)
9 transactions, 4,730,237 shares
Sum of shares × price per share: 71,344,746.25
Open-market sales (code S)
0 transactions, — shares

Totals add the filed transactions listed; they are counts of what was reported, not a measure of direction.

Showing 1–35 of 35

Insider transactions, newest first, as filed on SEC Forms 3, 4 and 5
DateReporting ownerCodeAcquired or disposedSharesPrice per share, as filedValue (derived)Shares owned afterDirect or indirectRule 10b5-1 boxNotesSource
2026-07-28 Filed 2026-07-28Aghazadeh Behzad Director · 10% owner · Other: See RemarksAvoro Capital Advisors LLC Director · 10% owner · Other: See RemarksAvoro Ventures LLC Director · Other: See Remarks
P

Open market or private purchase of non-derivative or derivative security

Common Stock, par value $0.0001 per share
Acquired (A)7,90518.25
144,266.25

Derived: shares × price per share. Exact value 144266.25.

3,088,888Indirect (I) See footnotesNo
F2, F3, F6, F4, F5
  • F2 The shares reported on these lines were purchased on behalf of Avoro Life Sciences in open market transactions on the dates provided in Column 2.
  • F3 Of the 3,088,888 shares reported in Column 5, 2,598,973 shares are held by Avoro Life Sciences and 489,915 shares are held by Avoro Ventures Fund.
  • F6 The amount reported in Column 5 includes 697,650 shares of Common Stock issuable upon conversion of shares of the Issuer's Series B Preferred Stock held by the Funds, which shares were reported on an as-converted basis in the Reporting Persons' Form 3 filed on July 23, 2026. Each share of Series B Preferred Stock was convertible into Common Stock on a one-for-0.1689 basis at the option of the holder and converted automatically into Common Stock, without the payment of any consideration, upon the closing of the IPO on July 27, 2026. No transaction is reported in Table I or Table II with respect to the conversion.
  • F4 The securities reported herein are held directly by Avoro Life Sciences and Avoro Ventures Fund. Avoro Capital Advisors LLC (Avoro Capital Advisors) serves as investment adviser to Avoro Life Sciences, and Avoro Ventures LLC (Avoro Ventures) serves as investment adviser to Avoro Ventures Fund. Dr. Aghazadeh serves as the portfolio manager and controlling person of Avoro Capital Advisors and Avoro Ventures. By virtue of these relationships, each of the Reporting Persons may be deemed to beneficially own the securities held by the Funds.
  • F5 Each Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that any Reporting Person is the beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. The shares reported herein are held on behalf of the Funds and other managed accounts, within the meaning of Rule 16a-1(a)(2).
Open filing 0000902664-26-003270 Read from the filing’s XML Dispute this row
2026-07-27 Filed 2026-07-29AH Bio Fund II, L.P. 10% ownerAH Equity Partners Bio II, L.L.C. 10% ownerAH Bio Fund III, L.P. 10% ownerAH Equity Partners Bio III, L.L.C. 10% ownerAndreessen Marc L 10% ownerHOROWITZ BENJAMIN A 10% owner
C

Conversion of derivative security

Common Stock
Acquired (A)2,051,742——2,051,742Indirect (I) By AH Bio Fund II, L.P.No
F1, F2
  • F1 Series A Preferred Stock and Series B Preferred Stock converted into Common Stock immediately prior to the closing of the Issuer's initial public offering for no additional consideration, on a 5.9218-for-one basis, and had no expiration date.
  • F2 The reported securities are held by AH Bio Fund II, L.P. (AH Bio Fund II), for itself and as nominee for AH Bio Fund II-B, L.P. AH Equity Partners Bio II, L.L.C. (AH EP Bio II) is the general partner of AH Bio Fund II and has sole voting and dispositive power with regard to the securities held by AH Bio Fund II for itself and as nominee. The managing members of AH EP Bio II are Marc Andreessen and Ben Horowitz. Marc Andreessen and Ben Horowitz may be deemed to share voting and dispositive power with respect to the securities held by AH Bio Fund II for itself and as nominee. Each of the Reporting Persons disclaims the existence of a group and disclaims beneficial ownership of the securities held by AH Bio Fund II for itself and as nominee (and this report shall not be deemed an admission that any such person is the beneficial owner of such securities), except to the extent of such person's pecuniary interest therein, if any.
Open filing 0001231919-26-000813 Read from the filing’s XML Dispute this row
2026-07-27 Filed 2026-07-29AH Bio Fund II, L.P. 10% ownerAH Equity Partners Bio II, L.L.C. 10% ownerAH Bio Fund III, L.P. 10% ownerAH Equity Partners Bio III, L.L.C. 10% ownerAndreessen Marc L 10% ownerHOROWITZ BENJAMIN A 10% owner
C

Conversion of derivative security

Common Stock
Acquired (A)697,650——697,650Indirect (I) By AH Bio Fund III, L.P.No
F1, F3, F4
  • F1 Series A Preferred Stock and Series B Preferred Stock converted into Common Stock immediately prior to the closing of the Issuer's initial public offering for no additional consideration, on a 5.9218-for-one basis, and had no expiration date.
  • F3 The reported securities are held by AH Bio Fund III, L.P. (AH Bio Fund III), for itself and as nominee for AH Bio Fund III-B, L.P., AH Bio Fund III-Q, L.P. and CLF Partners II, LP. AH Equity Partners Bio III, L.L.C. (AH EP Bio III) is the general partner of AH Bio Fund III and has sole voting and dispositive power with regard to the securities held by AH Bio Fund III for itself and as nominee. The managing members of AH EP Bio III are Marc Andreessen and Ben Horowitz. Marc Andreessen and Ben Horowitz may be deemed to share voting and dispositive power with respect to the securities held by AH Bio Fund III for itself and as nominee.
  • F4 (Continued from Footnote 3) Each of the Reporting Persons disclaims the existence of a group and disclaims beneficial ownership of the securities held by AH Bio Fund III for itself and as nominee (and this report shall not be deemed an admission that any such person is the beneficial owner of such securities), except to the extent of such person's pecuniary interest therein, if any.
Open filing 0001231919-26-000813 Read from the filing’s XML Dispute this row
2026-07-27 Filed 2026-07-29AH Bio Fund II, L.P. 10% ownerAH Equity Partners Bio II, L.L.C. 10% ownerAH Bio Fund III, L.P. 10% ownerAH Equity Partners Bio III, L.L.C. 10% ownerAndreessen Marc L 10% ownerHOROWITZ BENJAMIN A 10% owner
P

Open market or private purchase of non-derivative or derivative security

Common Stock
Acquired (A)333,33315
4,999,995

Derived: shares × price per share. Exact value 4999995.

2,385,075Indirect (I) By AH Bio Fund II, L.P.No
F2
  • F2 The reported securities are held by AH Bio Fund II, L.P. (AH Bio Fund II), for itself and as nominee for AH Bio Fund II-B, L.P. AH Equity Partners Bio II, L.L.C. (AH EP Bio II) is the general partner of AH Bio Fund II and has sole voting and dispositive power with regard to the securities held by AH Bio Fund II for itself and as nominee. The managing members of AH EP Bio II are Marc Andreessen and Ben Horowitz. Marc Andreessen and Ben Horowitz may be deemed to share voting and dispositive power with respect to the securities held by AH Bio Fund II for itself and as nominee. Each of the Reporting Persons disclaims the existence of a group and disclaims beneficial ownership of the securities held by AH Bio Fund II for itself and as nominee (and this report shall not be deemed an admission that any such person is the beneficial owner of such securities), except to the extent of such person's pecuniary interest therein, if any.
Open filing 0001231919-26-000813 Read from the filing’s XML Dispute this row
2026-07-27 Filed 2026-07-29AH Bio Fund II, L.P. 10% ownerAH Equity Partners Bio II, L.L.C. 10% ownerAH Bio Fund III, L.P. 10% ownerAH Equity Partners Bio III, L.L.C. 10% ownerAndreessen Marc L 10% ownerHOROWITZ BENJAMIN A 10% owner
C

Conversion of derivative security

Derivative security: Series A Preferred Stock — underlying Common Stock (2,051,742)
Disposed (D)12,150,0030—0Indirect (I) By AH Bio Fund II, L.P.No
F1, F2
  • F1 Series A Preferred Stock and Series B Preferred Stock converted into Common Stock immediately prior to the closing of the Issuer's initial public offering for no additional consideration, on a 5.9218-for-one basis, and had no expiration date.
  • F2 The reported securities are held by AH Bio Fund II, L.P. (AH Bio Fund II), for itself and as nominee for AH Bio Fund II-B, L.P. AH Equity Partners Bio II, L.L.C. (AH EP Bio II) is the general partner of AH Bio Fund II and has sole voting and dispositive power with regard to the securities held by AH Bio Fund II for itself and as nominee. The managing members of AH EP Bio II are Marc Andreessen and Ben Horowitz. Marc Andreessen and Ben Horowitz may be deemed to share voting and dispositive power with respect to the securities held by AH Bio Fund II for itself and as nominee. Each of the Reporting Persons disclaims the existence of a group and disclaims beneficial ownership of the securities held by AH Bio Fund II for itself and as nominee (and this report shall not be deemed an admission that any such person is the beneficial owner of such securities), except to the extent of such person's pecuniary interest therein, if any.
Open filing 0001231919-26-000813 Read from the filing’s XML Dispute this row
2026-07-27 Filed 2026-07-29AH Bio Fund II, L.P. 10% ownerAH Equity Partners Bio II, L.L.C. 10% ownerAH Bio Fund III, L.P. 10% ownerAH Equity Partners Bio III, L.L.C. 10% ownerAndreessen Marc L 10% ownerHOROWITZ BENJAMIN A 10% owner
C

Conversion of derivative security

Derivative security: Series B Preferred Stock — underlying Common Stock (697,650)
Disposed (D)4,131,3440—0Indirect (I) By AH Bio Fund III, L.P.No
F1, F3, F4
  • F1 Series A Preferred Stock and Series B Preferred Stock converted into Common Stock immediately prior to the closing of the Issuer's initial public offering for no additional consideration, on a 5.9218-for-one basis, and had no expiration date.
  • F3 The reported securities are held by AH Bio Fund III, L.P. (AH Bio Fund III), for itself and as nominee for AH Bio Fund III-B, L.P., AH Bio Fund III-Q, L.P. and CLF Partners II, LP. AH Equity Partners Bio III, L.L.C. (AH EP Bio III) is the general partner of AH Bio Fund III and has sole voting and dispositive power with regard to the securities held by AH Bio Fund III for itself and as nominee. The managing members of AH EP Bio III are Marc Andreessen and Ben Horowitz. Marc Andreessen and Ben Horowitz may be deemed to share voting and dispositive power with respect to the securities held by AH Bio Fund III for itself and as nominee.
  • F4 (Continued from Footnote 3) Each of the Reporting Persons disclaims the existence of a group and disclaims beneficial ownership of the securities held by AH Bio Fund III for itself and as nominee (and this report shall not be deemed an admission that any such person is the beneficial owner of such securities), except to the extent of such person's pecuniary interest therein, if any.
Open filing 0001231919-26-000813 Read from the filing’s XML Dispute this row
2026-07-27 Filed 2026-07-29ORBIMED ADVISORS LLC DirectorOrbiMed Capital GP VIII LLC Director
C

Conversion of derivative security

Common Stock
Acquired (A)348,825——348,825Indirect (I) See footnotesNo
F1, F3, F4
  • F1 Each share of Series B Preferred Stock automatically converted into shares of the Issuer's Common Stock on a one-for-0.1689 basis upon the closing of the Issuer's initial public offering on July 27, 2026 without payment of consideration. The Series B Preferred Stock has no expiration date.
  • F3 The shares are held directly by OrbiMed Private Investments VIII, LP (OPI VIII). OrbiMed Capital GP VIII LLC (GP VIII) is the general partner of OPI VIII. OrbiMed Advisors LLC (OrbiMed Advisors) is the managing member of GP VIII. By virtue of such relationships, GP VIII and OrbiMed Advisors may be deemed to have voting power and investment power over the securities held by OPI VIII and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPI VIII.
  • F4 This report on Form 4 is jointly filed by OrbiMed Advisors and GP VIII. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the Exchange Act), except to the extent of its pecuniary interest therein, if any. The Reporting Persons have designated a representative, Carl L. Gordon, a member of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any such entity or person is a beneficial owner of such securities for purpose of Section 16 of the Exchange Act, or for any other purpose.
Open filing 0000947871-26-000733 Read from the filing’s XML Dispute this row
2026-07-27 Filed 2026-07-29ORBIMED ADVISORS LLC DirectorOrbiMed Capital GP VIII LLC Director
P

Open market or private purchase of non-derivative or derivative security

Common Stock
Acquired (A)1,000,00015
15,000,000

Derived: shares × price per share. Exact value 15000000.

1,348,825Indirect (I) See footnotesNo
F2, F3, F4
  • F2 Reflects shares of the Issuer's Common Stock purchased in the Issuer's initial public offering.
  • F3 The shares are held directly by OrbiMed Private Investments VIII, LP (OPI VIII). OrbiMed Capital GP VIII LLC (GP VIII) is the general partner of OPI VIII. OrbiMed Advisors LLC (OrbiMed Advisors) is the managing member of GP VIII. By virtue of such relationships, GP VIII and OrbiMed Advisors may be deemed to have voting power and investment power over the securities held by OPI VIII and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPI VIII.
  • F4 This report on Form 4 is jointly filed by OrbiMed Advisors and GP VIII. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the Exchange Act), except to the extent of its pecuniary interest therein, if any. The Reporting Persons have designated a representative, Carl L. Gordon, a member of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any such entity or person is a beneficial owner of such securities for purpose of Section 16 of the Exchange Act, or for any other purpose.
Open filing 0000947871-26-000733 Read from the filing’s XML Dispute this row
2026-07-27 Filed 2026-07-29ORBIMED ADVISORS LLC DirectorOrbiMed Capital GP VIII LLC Director
C

Conversion of derivative security

Derivative security: Series B Preferred Stock — underlying Common Stock (348,825)
Disposed (D)2,065,6720—0Indirect (I) See footnotesNo
F1, F3, F4
  • F1 Each share of Series B Preferred Stock automatically converted into shares of the Issuer's Common Stock on a one-for-0.1689 basis upon the closing of the Issuer's initial public offering on July 27, 2026 without payment of consideration. The Series B Preferred Stock has no expiration date.
  • F3 The shares are held directly by OrbiMed Private Investments VIII, LP (OPI VIII). OrbiMed Capital GP VIII LLC (GP VIII) is the general partner of OPI VIII. OrbiMed Advisors LLC (OrbiMed Advisors) is the managing member of GP VIII. By virtue of such relationships, GP VIII and OrbiMed Advisors may be deemed to have voting power and investment power over the securities held by OPI VIII and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPI VIII.
  • F4 This report on Form 4 is jointly filed by OrbiMed Advisors and GP VIII. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the Exchange Act), except to the extent of its pecuniary interest therein, if any. The Reporting Persons have designated a representative, Carl L. Gordon, a member of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any such entity or person is a beneficial owner of such securities for purpose of Section 16 of the Exchange Act, or for any other purpose.
Open filing 0000947871-26-000733 Read from the filing’s XML Dispute this row
2026-07-27 Filed 2026-07-29GORDON CARL L Director
C

Conversion of derivative security

Common Stock
Acquired (A)348,825——348,825Indirect (I) See footnotesNo
F1, F3, F4
  • F1 Each share of Series B Preferred Stock automatically converted into shares of the Issuer's Common Stock on a one-for-0.1689 basis upon the closing of the Issuer's initial public offering on July 27, 2026 without payment of consideration. The Series B Preferred Stock has no expiration date.
  • F3 The shares are held directly by OrbiMed Private Investments VIII, LP (OPI VIII). OrbiMed Capital GP VIII LLC (GP VIII) is the general partner of OPI VIII. OrbiMed Advisors LLC (OrbiMed Advisors) is the managing member of GP VIII. By virtue of such relationships, GP VIII and OrbiMed Advisors may be deemed to have voting power and investment power over the securities held by OPI VIII and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of the Reporting Person, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPI VIII.
  • F4 Each of the Reporting Person, OrbiMed Advisors and GP VIII disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the Exchange Act), except to the extent of his or its pecuniary interest therein, if any. This report shall not be deemed an admission that any such person or entity, including the Reporting Person, is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose.
Open filing 0000947871-26-000734 Read from the filing’s XML Dispute this row
2026-07-27 Filed 2026-07-29GORDON CARL L Director
P

Open market or private purchase of non-derivative or derivative security

Common Stock
Acquired (A)1,000,00015
15,000,000

Derived: shares × price per share. Exact value 15000000.

1,348,825Indirect (I) See footnotesNo
F2, F3, F4
  • F2 Reflects shares of the Issuer's Common Stock purchased in the Issuer's initial public offering.
  • F3 The shares are held directly by OrbiMed Private Investments VIII, LP (OPI VIII). OrbiMed Capital GP VIII LLC (GP VIII) is the general partner of OPI VIII. OrbiMed Advisors LLC (OrbiMed Advisors) is the managing member of GP VIII. By virtue of such relationships, GP VIII and OrbiMed Advisors may be deemed to have voting power and investment power over the securities held by OPI VIII and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of the Reporting Person, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPI VIII.
  • F4 Each of the Reporting Person, OrbiMed Advisors and GP VIII disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the Exchange Act), except to the extent of his or its pecuniary interest therein, if any. This report shall not be deemed an admission that any such person or entity, including the Reporting Person, is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose.
Open filing 0000947871-26-000734 Read from the filing’s XML Dispute this row
2026-07-27 Filed 2026-07-29GORDON CARL L Director
C

Conversion of derivative security

Derivative security: Series B Preferred Stock — underlying Common Stock (348,825)
Disposed (D)2,065,6720—0Indirect (I) See footnotesNo
F1, F3, F4
  • F1 Each share of Series B Preferred Stock automatically converted into shares of the Issuer's Common Stock on a one-for-0.1689 basis upon the closing of the Issuer's initial public offering on July 27, 2026 without payment of consideration. The Series B Preferred Stock has no expiration date.
  • F3 The shares are held directly by OrbiMed Private Investments VIII, LP (OPI VIII). OrbiMed Capital GP VIII LLC (GP VIII) is the general partner of OPI VIII. OrbiMed Advisors LLC (OrbiMed Advisors) is the managing member of GP VIII. By virtue of such relationships, GP VIII and OrbiMed Advisors may be deemed to have voting power and investment power over the securities held by OPI VIII and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of the Reporting Person, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPI VIII.
  • F4 Each of the Reporting Person, OrbiMed Advisors and GP VIII disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the Exchange Act), except to the extent of his or its pecuniary interest therein, if any. This report shall not be deemed an admission that any such person or entity, including the Reporting Person, is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose.
Open filing 0000947871-26-000734 Read from the filing’s XML Dispute this row
2026-07-27 Filed 2026-07-29Doudna Jennifer A 10% owner
C

Conversion of derivative security

Common Stock
Acquired (A)12,511——603,547Direct (D) No
F1
  • F1 Each share of Series A-1 Preferred Stock is convertible into Common Stock on a one-for 0.1689 basis at the option of the holder, and will convert automatically upon closing of the Issuer's initial public offering without payment of consideration. The Series A-1 Preferred Stock has no expiration date.
Open filing 0001739090-26-000010 Read from the filing’s XML Dispute this row
2026-07-27 Filed 2026-07-29Doudna Jennifer A 10% owner
C

Conversion of derivative security

Derivative security: Series A-1 Preferred Stock — underlying Common Stock (12,511)
Disposed (D)74,088——0Direct (D) No
F1
  • F1 Each share of Series A-1 Preferred Stock is convertible into Common Stock on a one-for 0.1689 basis at the option of the holder, and will convert automatically upon closing of the Issuer's initial public offering without payment of consideration. The Series A-1 Preferred Stock has no expiration date.
Open filing 0001739090-26-000010 Read from the filing’s XML Dispute this row
2026-07-24 Filed 2026-07-28Aghazadeh Behzad Director · 10% owner · Other: See RemarksAvoro Capital Advisors LLC Director · 10% owner · Other: See RemarksAvoro Ventures LLC Director · Other: See Remarks
P

Open market or private purchase of non-derivative or derivative security

Common Stock, par value $0.0001 per share
Acquired (A)2,333,33315.00
34,999,995

Derived: shares × price per share. Exact value 34999995.00.

3,030,983Indirect (I) See footnotesNo
F1, F6, F4, F5
  • F1 The shares reported on this line were purchased from underwriters in the Issuer's initial public offering (the IPO) at the initial public offering price of $15.00 per share. Of such shares, 2,066,666 shares were purchased on behalf of Avoro Life Sciences Fund LLC (Avoro Life Sciences) and 266,667 shares were purchased on behalf of Avoro Ventures Fund L.P. (Avoro Ventures Fund and, together with Avoro Life Sciences, the Funds).
  • F6 The amount reported in Column 5 includes 697,650 shares of Common Stock issuable upon conversion of shares of the Issuer's Series B Preferred Stock held by the Funds, which shares were reported on an as-converted basis in the Reporting Persons' Form 3 filed on July 23, 2026. Each share of Series B Preferred Stock was convertible into Common Stock on a one-for-0.1689 basis at the option of the holder and converted automatically into Common Stock, without the payment of any consideration, upon the closing of the IPO on July 27, 2026. No transaction is reported in Table I or Table II with respect to the conversion.
  • F4 The securities reported herein are held directly by Avoro Life Sciences and Avoro Ventures Fund. Avoro Capital Advisors LLC (Avoro Capital Advisors) serves as investment adviser to Avoro Life Sciences, and Avoro Ventures LLC (Avoro Ventures) serves as investment adviser to Avoro Ventures Fund. Dr. Aghazadeh serves as the portfolio manager and controlling person of Avoro Capital Advisors and Avoro Ventures. By virtue of these relationships, each of the Reporting Persons may be deemed to beneficially own the securities held by the Funds.
  • F5 Each Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that any Reporting Person is the beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. The shares reported herein are held on behalf of the Funds and other managed accounts, within the meaning of Rule 16a-1(a)(2).
Open filing 0000902664-26-003270 Read from the filing’s XML Dispute this row
2026-07-24 Filed 2026-07-28Aghazadeh Behzad Director · 10% owner · Other: See RemarksAvoro Capital Advisors LLC Director · 10% owner · Other: See RemarksAvoro Ventures LLC Director · Other: See Remarks
P

Open market or private purchase of non-derivative or derivative security

Common Stock, par value $0.0001 per share
Acquired (A)50,00022.31
1,115,500

Derived: shares × price per share. Exact value 1115500.00.

3,080,983Indirect (I) See footnotesNo
F2, F6, F4, F5
  • F2 The shares reported on these lines were purchased on behalf of Avoro Life Sciences in open market transactions on the dates provided in Column 2.
  • F6 The amount reported in Column 5 includes 697,650 shares of Common Stock issuable upon conversion of shares of the Issuer's Series B Preferred Stock held by the Funds, which shares were reported on an as-converted basis in the Reporting Persons' Form 3 filed on July 23, 2026. Each share of Series B Preferred Stock was convertible into Common Stock on a one-for-0.1689 basis at the option of the holder and converted automatically into Common Stock, without the payment of any consideration, upon the closing of the IPO on July 27, 2026. No transaction is reported in Table I or Table II with respect to the conversion.
  • F4 The securities reported herein are held directly by Avoro Life Sciences and Avoro Ventures Fund. Avoro Capital Advisors LLC (Avoro Capital Advisors) serves as investment adviser to Avoro Life Sciences, and Avoro Ventures LLC (Avoro Ventures) serves as investment adviser to Avoro Ventures Fund. Dr. Aghazadeh serves as the portfolio manager and controlling person of Avoro Capital Advisors and Avoro Ventures. By virtue of these relationships, each of the Reporting Persons may be deemed to beneficially own the securities held by the Funds.
  • F5 Each Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that any Reporting Person is the beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. The shares reported herein are held on behalf of the Funds and other managed accounts, within the meaning of Rule 16a-1(a)(2).
Open filing 0000902664-26-003270 Read from the filing’s XML Dispute this row
2026-07-23 Filed 2026-07-28Staahl Brett 10% owner
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (Right to Buy) — underlying Common Stock (19,385) — exercise price 15
Acquired (A)19,3850—19,385Direct (D) No
F3
  • F3 The options will vest as to 1/48 of the total shares monthly over four years, with the first tranche scheduled to vest on August 23, 2026, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
Open filing 0002147277-26-000003 Read from the filing’s XML Dispute this row
2026-07-23 Filed 2026-07-28Staahl Brett 10% owner
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Performance-based Stock Option (Right to Buy) — underlying Common Stock (19,385) — exercise price 15
Acquired (A)19,3850—19,385Direct (D) No
F4
  • F4 The options are eligible to vest upon the achievement of certain market-based performance criteria during a performance period beginning on July 23, 2026 and ending on July 23, 2029, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
Open filing 0002147277-26-000003 Read from the filing’s XML Dispute this row
2026-07-23 Filed 2026-07-27Lucas Svetlana Officer: Chief Business Officer
P

Open market or private purchase of non-derivative or derivative security

Common Stock
Acquired (A)3,00015
45,000

Derived: shares × price per share. Exact value 45000.

3,000Indirect (I) By SpouseNo— Open filing 0001781292-26-000007 Read from the filing’s XML Dispute this row
2026-07-23 Filed 2026-07-27Lucas Svetlana Officer: Chief Business Officer
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (Right to Buy) — underlying Common Stock (109,426) — exercise price 15
Acquired (A)109,4260—109,426Direct (D) No
F3
  • F3 The options will vest as to 1/48 of the total shares monthly over four years, with the first tranche scheduled to vest on August 23, 2026, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
Open filing 0001781292-26-000007 Read from the filing’s XML Dispute this row
2026-07-23 Filed 2026-07-27Lucas Svetlana Officer: Chief Business Officer
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Performance-based Stock Option (Right to Buy) — underlying Common Stock (109,426) — exercise price 15
Acquired (A)109,4260—109,426Direct (D) No
F4
  • F4 The options are eligible to vest upon the achievement of certain market-based performance criteria during a performance period beginning on July 23, 2026 and ending on July 23, 2029, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
Open filing 0001781292-26-000007 Read from the filing’s XML Dispute this row
2026-07-23 Filed 2026-07-27Oakes Benjamin L. Director · Officer: President, CEO · Other: Chairman of the Board
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (Right to Buy) — underlying Common Stock (264,784) — exercise price 15
Acquired (A)264,7840—264,784Direct (D) No
F3
  • F3 The options will vest as to 1/48 of the total shares monthly over four years, with the first tranche scheduled to vest on August 23, 2026, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
Open filing 0002127814-26-000004 Read from the filing’s XML Dispute this row
2026-07-23 Filed 2026-07-27Oakes Benjamin L. Director · Officer: President, CEO · Other: Chairman of the Board
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Performance-based Stock Option (Right to Buy) — underlying Common Stock (429,599) — exercise price 15
Acquired (A)429,5990—429,599Direct (D) No
F4
  • F4 The options are eligible to vest upon the achievement of certain market-based performance criteria during a performance period beginning on July 23, 2026 and ending on July 23, 2029, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
Open filing 0002127814-26-000004 Read from the filing’s XML Dispute this row
2026-07-23 Filed 2026-07-27Watson James Dean Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (Right to Buy) — underlying Common Stock (14,725) — exercise price 15
Acquired (A)14,7250—14,725Direct (D) No
F1
  • F1 The options will vest as to 1/3 of the total shares on each of July 23, 2027, July 23, 2028 and July 23, 2029, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
Open filing 0002130384-26-000004 Read from the filing’s XML Dispute this row
2026-07-23 Filed 2026-07-27Aghazadeh Behzad Director · Other: See RemarksAvoro Capital Advisors LLC Director · Other: See RemarksAvoro Ventures LLC Director · Other: See Remarks
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (Right to Buy) — underlying Common Stock (14,725) — exercise price 15
Acquired (A)14,7250—14,725Direct (D) No
F1, F2, F3
  • F1 The options will vest as to 1/3 of the total shares on each of July 23, 2027, July 23, 2028 and July 23, 2029, subject to Behzad Aghazadeh's (Dr. Aghazadeh) provision of service to the Issuer on each vesting date.
  • F2 This Form 4 is filed by Dr. Aghazadeh, Avoro Capital Advisors LLC, a Delaware limited liability company (Avoro Capital Advisors), and Avoro Ventures LLC, a Delaware limited liability company (Avoro Ventures, together with Dr. Aghazadeh and Avoro Capital Advisors, the Reporting Persons). Dr. Aghazadeh serves as the portfolio manager and controlling person of Avoro Capital Advisors and Avoro Ventures LLC.
  • F3 The filing of this statement shall not be deemed an admission that any Reporting Person is the beneficial owner of the securities reported herein for the purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise. Each of the Reporting Persons expressly disclaims beneficial ownership of the securities reported herein except to the extent of its or his pecuniary interest therein.
Open filing 0000902664-26-003254 Read from the filing’s XML Dispute this row
2026-07-23 Filed 2026-07-27Bleharski Joshua Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (Right to Buy) — underlying Common Stock (14,725) — exercise price 15
Acquired (A)14,7250—14,725Direct (D) No
F1
  • F1 The options will vest as to 1/3 of the total shares on each of July 23, 2027, July 23, 2028 and July 23, 2029, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
Open filing 0002075052-26-000004 Read from the filing’s XML Dispute this row
2026-07-23 Filed 2026-07-27GORDON CARL L Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (Right to Buy) — underlying Common Stock (14,725) — exercise price 15
Acquired (A)14,7250—14,725Direct (D) No
F1
  • F1 The options will vest as to 1/3 of the total shares on each of July 23, 2027, July 23, 2028 and July 23, 2029, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
Open filing 0001282930-26-000004 Read from the filing’s XML Dispute this row
2026-07-23 Filed 2026-07-27Parrot David Officer: Chief Financial Officer
P

Open market or private purchase of non-derivative or derivative security

Common Stock
Acquired (A)1,33315
19,995

Derived: shares × price per share. Exact value 19995.

1,333Indirect (I) By SpouseNo— Open filing 0002127908-26-000004 Read from the filing’s XML Dispute this row
2026-07-23 Filed 2026-07-27Parrot David Officer: Chief Financial Officer
P

Open market or private purchase of non-derivative or derivative security

Common Stock
Acquired (A)1,33315
19,995

Derived: shares × price per share. Exact value 19995.

1,333Indirect (I) By ChildNo— Open filing 0002127908-26-000004 Read from the filing’s XML Dispute this row
2026-07-23 Filed 2026-07-27Parrot David Officer: Chief Financial Officer
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (Right to Buy) — underlying Common Stock (109,426) — exercise price 15
Acquired (A)109,4260—109,426Direct (D) No
F3
  • F3 The options will vest as to 1/48 of the total shares monthly over four years, with the first tranche scheduled to vest on August 23, 2026, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
Open filing 0002127908-26-000004 Read from the filing’s XML Dispute this row
2026-07-23 Filed 2026-07-27Parrot David Officer: Chief Financial Officer
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Performance-based Stock Option (Right to Buy) — underlying Common Stock (109,426) — exercise price 15
Acquired (A)109,4260—109,426Direct (D) No
F4
  • F4 The options are eligible to vest upon the achievement of certain market-based performance criteria during a performance period beginning on July 23, 2026 and ending on July 23, 2029, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
Open filing 0002127908-26-000004 Read from the filing’s XML Dispute this row
2026-03-13 Filed 2026-07-28Staahl Brett 10% owner
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (Right to Buy) — underlying Common Stock (4,755) — exercise price 19.13
Acquired (A)4,7550—4,755Direct (D) No
F1, F2
  • F1 The transaction occurred prior to the Issuer's registration of a class of equity securities under Section 12 of the Exchange Act in connection with the Issuer's initial public offering, and the transaction is reported herein pursuant to Rule 16a-2(a).
  • F2 The option is fully vested.
Open filing 0002147277-26-000003 Read from the filing’s XML Dispute this row
2026-03-13 Filed 2026-07-27Lucas Svetlana Officer: Chief Business Officer
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (Right to Buy) — underlying Common Stock (9,547) — exercise price 19.13
Acquired (A)9,5470—9,547Direct (D) No
F1, F2
  • F1 The transaction occurred prior to the Issuer's registration of a class of equity securities under Section 12 of the Exchange Act in connection with the Issuer's initial public offering, and the transaction is reported herein pursuant to Rule 16a-2(a).
  • F2 The option is fully vested.
Open filing 0001781292-26-000007 Read from the filing’s XML Dispute this row
2026-03-13 Filed 2026-07-27Oakes Benjamin L. Director · Officer: President, CEO · Other: Chairman of the Board
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (Right to Buy) — underlying Common Stock (12,969) — exercise price 19.13
Acquired (A)12,9690—12,969Direct (D) No
F1, F2
  • F1 The transaction occurred prior to the Issuer's registration of a class of equity securities under Section 12 of the Exchange Act in connection with the Issuer's initial public offering, and the transaction is reported herein pursuant to Rule 16a-2(a).
  • F2 The option is fully vested.
Open filing 0002127814-26-000004 Read from the filing’s XML Dispute this row
2026-03-13 Filed 2026-07-27Parrot David Officer: Chief Financial Officer
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (Right to Buy) — underlying Common Stock (8,909) — exercise price 19.13
Acquired (A)8,9090—8,909Direct (D) No
F1, F2
  • F1 The transaction occurred prior to the Issuer's registration of a class of equity securities under Section 12 of the Exchange Act in connection with the Issuer's initial public offering, and the transaction is reported herein pursuant to Rule 16a-2(a).
  • F2 The option is fully vested.
Open filing 0002127908-26-000004 Read from the filing’s XML Dispute this row

Institutional holders (Form 13F)

Quarter ending 2026-09-30: 8,793 filings read, the latest filed 2026-11-17. Prior quarter ending 2026-06-30: 9,164 filings read.

Showing 1–50 of 62

Institutional holders, largest position first, as filed
ManagerShares or principalValue as filedChange from the prior quarterSource
a16z Capital Management, L.L.C. 3,082,725 SH56,737,554 dollarsNot in the prior quarter’s filings read Open filing 0001540358-26-000014 Filed 2026-11-16 Dispute this row
Avoro Capital Advisors LLC 2,598,973 SH47,834,098 dollarsNot in the prior quarter’s filings read Open filing 0001104659-26-127608 Filed 2026-11-16 Dispute this row
RA CAPITAL MANAGEMENT, L.P. 1,802,178 SH33,169,086 dollarsNot in the prior quarter’s filings read Open filing 0001104659-26-128411 Filed 2026-11-16 Dispute this row
ORBIMED ADVISORS LLC 1,348,825 SH24,825,124 dollarsNot in the prior quarter’s filings read Open filing 0001172661-26-005349 Filed 2026-11-16 Dispute this row
PERCEPTIVE ADVISORS LLC 920,341 SH16,938,876 dollarsNot in the prior quarter’s filings read Open filing 0001012975-26-001063 Filed 2026-11-16 Dispute this row
ARK Investment Management LLC 786,921 SH14,483,278 dollarsNot in the prior quarter’s filings read Open filing 0001104659-26-126785 Filed 2026-11-13 Dispute this row
BAKER BROS. ADVISORS LP 688,691 SH12,675,358 dollarsNot in the prior quarter’s filings read Open filing 0001104659-26-128308 Filed 2026-11-16 Dispute this row
PRICE T ROWE ASSOCIATES INC /MD/ Partly reported under another manager684,706 SH12,603 dollarsNot in the prior quarter’s filings read Open filing 0000080255-26-000736 Filed 2026-11-16 Dispute this row
BlackRock, Inc. Partly reported under another manager679,786 SH12,511,461 dollarsNot in the prior quarter’s filings read Open filing 0002012383-26-003985 Filed 2026-11-13 Dispute this row
Sanofi 500,000 SH9,202,500 dollarsNot in the prior quarter’s filings read Open filing 0001193125-26-448717 Filed 2026-11-05 Dispute this row
VANGUARD CAPITAL MANAGEMENT LLC 407,630 SH7,502,430 dollarsNot in the prior quarter’s filings read Open filing 0002100119-26-001711 Filed 2026-11-13 Dispute this row
FRANKLIN TEMPLETON INC Partly reported under another manager380,019 SH6,376,719 dollarsNot in the prior quarter’s filings read Open filing 0000038777-26-000291 Filed 2026-11-12 Dispute this row
ADAGE CAPITAL PARTNERS GP, L.L.C. 380,000 SH6,993,900 dollarsNot in the prior quarter’s filings read Open filing 0001172661-26-005200 Filed 2026-11-16 Dispute this row
FARALLON CAPITAL MANAGEMENT, L.L.C. 380,000 SH6,993,900 dollarsNot in the prior quarter’s filings read Open filing 0000908834-26-000540 Filed 2026-11-16 Dispute this row
GEODE CAPITAL MANAGEMENT, LLC Partly reported under another manager245,412 SH4,518,022 dollarsNot in the prior quarter’s filings read Open filing 0001214717-26-000012 Filed 2026-11-06 Dispute this row
STATE STREET CORP Partly reported under another manager171,147 SH3,149,961 dollarsNot in the prior quarter’s filings read Open filing 0000093751-26-000747 Filed 2026-11-12 Dispute this row
Alyeska Investment Group, L.P. 150,000 SH2,760,750 dollarsNot in the prior quarter’s filings read Open filing 0001172661-26-005329 Filed 2026-11-16 Dispute this row
Menlo Ventures Management, L.P. 97,690 SH1,797,984 dollarsNot in the prior quarter’s filings read Open filing 0001911541-26-000014 Filed 2026-11-06 Dispute this row
TD ASSET MANAGEMENT INC 83,342 SH1,919,366 dollarsNot in the prior quarter’s filings read Open filing 0001193125-26-460060 Filed 2026-11-13 Dispute this row
Amova Asset Management Americas, Inc. Partly reported under another manager74,910 SH1,378,344 dollarsNot in the prior quarter’s filings read Open filing 0001140361-26-043552 Filed 2026-11-13 Dispute this row
Sumitomo Mitsui Trust Group, Inc. Partly reported under another manager74,910 SH1,378,719 dollarsNot in the prior quarter’s filings read Open filing 0001214659-26-013361 Filed 2026-10-29 Dispute this row
NORTHERN TRUST CORP Partly reported under another manager74,721 SH1,375,240 dollarsNot in the prior quarter’s filings read Open filing 0000073124-26-000067 Filed 2026-11-16 Dispute this row
UBS Group AG Partly reported under another manager71,067 SH1,307,988 dollarsNot in the prior quarter’s filings read Open filing 0001610520-26-000121 Filed 2026-11-10 Dispute this row
VANGUARD PORTFOLIO MANAGEMENT LLC 67,039 SH1,233,853 dollarsNot in the prior quarter’s filings read Open filing 0002100121-26-001150 Filed 2026-11-13 Dispute this row
VANGUARD FIDUCIARY TRUST CO 64,267 SH1,182,834 dollarsNot in the prior quarter’s filings read Open filing 0000933478-26-000017 Filed 2026-11-13 Dispute this row
Nuveen, LLC Partly reported under another manager41,470 SH763,255 dollarsNot in the prior quarter’s filings read Open filing 0000930413-26-003284 Filed 2026-11-10 Dispute this row
IQ EQ FUND MANAGEMENT (IRELAND) Ltd 40,876 SH0 dollarsNot in the prior quarter’s filings read Open filing 0001213900-26-119414 Filed 2026-11-13 Dispute this row
Longaeva Partners L.P. Partly reported under another manager34,034 SH626,396 dollarsNot in the prior quarter’s filings read Open filing 0001193125-26-463222 Filed 2026-11-16 Dispute this row
CHARLES SCHWAB INVESTMENT MANAGEMENT INC 31,644 SH582,408 dollarsNot in the prior quarter’s filings read Open filing 0000884546-26-000417 Filed 2026-11-16 Dispute this row
BANK OF AMERICA CORP /DE/ Partly reported under another manager27,589 SH507,776 dollarsNot in the prior quarter’s filings read Open filing 0000070858-26-000589 Filed 2026-11-16 Dispute this row
Point72 Asset Management, L.P. 22,771 SH419,100 dollarsNot in the prior quarter’s filings read Open filing 0000919574-26-008126 Filed 2026-11-16 Dispute this row
WELLS FARGO COMPANY/MN Partly reported under another manager22,500 SH414,112 dollarsNot in the prior quarter’s filings read Open filing 0000072971-26-000342 Filed 2026-11-16 Dispute this row
GOLDMAN SACHS GROUP INC Partly reported under another manager21,635 SH398,192 dollarsNot in the prior quarter’s filings read Open filing 0000886982-26-000647 Filed 2026-11-16 Dispute this row
Bank of New York Mellon Corp Partly reported under another manager20,396 SH375,389 dollarsNot in the prior quarter’s filings read Open filing 0001390777-26-000121 Filed 2026-11-05 Dispute this row
Focus Partners Wealth 20,025 SH368,560 dollarsNot in the prior quarter’s filings read Open filing 0001542153-26-000021 Filed 2026-11-12 Dispute this row
SUSQUEHANNA INTERNATIONAL GROUP, LLP Partly reported under another manager13,641 SH251,063 dollarsNot in the prior quarter’s filings read Open filing 0001446194-26-000009 Filed 2026-11-16 Dispute this row
SEVEN GRAND MANAGERS, LLC 10,000 SH184,050 dollarsNot in the prior quarter’s filings read Open filing 0001420506-26-002775 Filed 2026-11-16 Dispute this row
RHUMBLINE ADVISERS 8,897 SH163,742 dollarsNot in the prior quarter’s filings read Open filing 0001115418-26-000015 Filed 2026-11-10 Dispute this row
MORGAN STANLEY Partly reported under another manager8,536 SH157,106 dollarsNot in the prior quarter’s filings read Open filing 0000895421-26-000309 Filed 2026-11-13 Dispute this row
DEUTSCHE BANK AG\ Partly reported under another manager8,269 SH152,233 dollarsNot in the prior quarter’s filings read Open filing 0000948046-26-000083 Filed 2026-11-06 Dispute this row
JPMORGAN CHASE CO Partly reported under another manager6,028 SH138,825 dollarsNot in the prior quarter’s filings read Open filing 0000019617-26-000404 Filed 2026-11-12 Dispute this row
MetLife Investment Management, LLC Partly reported under another manager5,814 SH107,007 dollarsNot in the prior quarter’s filings read Open filing 0001628280-26-073956 Filed 2026-11-16 Dispute this row
CITIGROUP INC Partly reported under another manager4,742 SH87,277 dollarsNot in the prior quarter’s filings read Open filing 0000831001-26-000052 Filed 2026-11-04 Dispute this row
MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Partly reported under another manager4,636 SH85,326 dollarsNot in the prior quarter’s filings read Open filing 0000905148-26-004850 Filed 2026-11-16 Dispute this row
KAYNE ANDERSON RUDNICK INVESTMENT MANAGEMENT LLC 4,195 SH77,209 dollarsNot in the prior quarter’s filings read Open filing 0001398344-26-020056 Filed 2026-11-13 Dispute this row
Vanguard Global Advisers, LLC 3,592 SH66,111 dollarsNot in the prior quarter’s filings read Open filing 0001811242-26-000017 Filed 2026-11-13 Dispute this row
TEMA ETFS LLC 3,046 SH56,062 dollarsNot in the prior quarter’s filings read Open filing 0001829126-26-011223 Filed 2026-10-16 Dispute this row
STRS OHIO 2,600 SH47,853 dollarsNot in the prior quarter’s filings read Open filing 0000820478-26-000018 Filed 2026-10-30 Dispute this row
BNP PARIBAS FINANCIAL MARKETS Partly reported under another manager2,400 SH44,172 dollarsNot in the prior quarter’s filings read Open filing 0001166588-26-000012 Filed 2026-11-12 Dispute this row
Police Firemen's Retirement System of New Jersey Partly reported under another manager2,289 SH42,129 dollarsNot in the prior quarter’s filings read Open filing 0002040686-26-000007 Filed 2026-11-09 Dispute this row
  • Form 13F covers long positions in Section 13(f) securities only: no short positions and no securities outside that list.
  • A manager that has not yet filed for the latest quarter is absent, not at zero; filings are due up to 45 days after quarter end.
  • A change is the difference between two quarter-end snapshots, not a trade.
  • A position reported under another manager may also appear in that manager’s filing; rows are not added together.
  • Holdings the securities list cannot place with this company, or places ambiguously, are not shown.

5% holders (Schedule 13D and 13G)

Schedules filed in the SEC’s structured format (late 2024 onward) are read here. Earlier schedules are free text and are not read.

5% holders, newest event first, as filed
HolderPercent of classShares heldEvent dateFormSource
AH Bio Fund II, L.P. Common Stock, $0.001 par value per share12.62,385,075.0009/30/2026 Filed 2026-11-16SCHEDULE 13GOpen filing 0001725721-26-000009 Dispute this row
AH Equity Partners Bio II, L.L.C. Common Stock, $0.001 par value per share12.62,385,075.0009/30/2026 Filed 2026-11-16SCHEDULE 13GOpen filing 0001725721-26-000009 Dispute this row
AH Bio Fund III, L.P. Common Stock, $0.001 par value per share3.7697,650.0009/30/2026 Filed 2026-11-16SCHEDULE 13GOpen filing 0001725721-26-000009 Dispute this row
AH Equity Partners Bio III, L.L.C. Common Stock, $0.001 par value per share3.7697,650.0009/30/2026 Filed 2026-11-16SCHEDULE 13GOpen filing 0001725721-26-000009 Dispute this row
Marc L. Andreessen Common Stock, $0.001 par value per share16.33,082,725.0009/30/2026 Filed 2026-11-16SCHEDULE 13GOpen filing 0001725721-26-000009 Dispute this row
Benjamin A. Horowitz Common Stock, $0.001 par value per share16.33,082,725.0009/30/2026 Filed 2026-11-16SCHEDULE 13GOpen filing 0001725721-26-000009 Dispute this row
RA Capital Management, L.P. Common Stock, $0.001 par value per share9.61,802,178.0007/27/2026 Filed 2026-08-03SCHEDULE 13GOpen filing 0001346824-26-000210 Dispute this row
Peter Kolchinsky Common Stock, $0.001 par value per share9.61,802,178.0007/27/2026 Filed 2026-08-03SCHEDULE 13GOpen filing 0001346824-26-000210 Dispute this row
Rajeev Shah Common Stock, $0.001 par value per share9.61,802,178.0007/27/2026 Filed 2026-08-03SCHEDULE 13GOpen filing 0001346824-26-000210 Dispute this row
RA Capital Healthcare Fund, L.P. Common Stock, $0.001 par value per share9.11,714,582.0007/27/2026 Filed 2026-08-03SCHEDULE 13GOpen filing 0001346824-26-000210 Dispute this row
ORBIMED ADVISORS LLC Common Stock7.21,348,825.0007/27/2026 Filed 2026-07-29SCHEDULE 13DOpen filing 0000947871-26-000732 Dispute this row
ORBIMED CAPITAL GP VIII LLC Common Stock7.21,348,825.0007/27/2026 Filed 2026-07-29SCHEDULE 13DOpen filing 0000947871-26-000732 Dispute this row
Avoro Capital Advisors LLC Common Stock, $0.001 par value per share13.782,598,973.0007/24/2026 Filed 2026-07-30SCHEDULE 13DOpen filing 0000902664-26-003281 Dispute this row
Avoro Ventures LLC Common Stock, $0.001 par value per share2.60489,915.0007/24/2026 Filed 2026-07-30SCHEDULE 13DOpen filing 0000902664-26-003281 Dispute this row
Aghazadeh Behzad Common Stock, $0.001 par value per share16.373,088,888.0007/24/2026 Filed 2026-07-30SCHEDULE 13DOpen filing 0000902664-26-003281 Dispute this row
ELI LILLY Co Common stock, $0.001 par value per share7.31,388,161.0007/23/2026 Filed 2026-07-30SCHEDULE 13DOpen filing 0000059478-26-000072 Dispute this row

Percent is of the class the filing names, as the holder stated it. Members of a group each report the group’s shares, so rows are not added together.

What was read

2,241,208 filings read, dated 2004-06-14 to 2026-11-17: Forms 3, 3/A, 4, 4/A, 5, 5/A.

Years can be incomplete while the archive is still being read. A year with few filings here is not a statement that few were made.

Filings read, by filing year
Filing yearFilings read
20151
2016204,322
2017202,494
2018202,048
2019193,638
2020144,184
2021224,474
2022158,941
2023199,811
2024209,823
2025235,520
2026260,174

Filings made before the SEC required XML are listed, not extracted.

Back to Scribe Therapeutics, Inc.